Validation of a commercial dry-form broth microdilution device (sensititre) for testing tedizolid, a new oxazolidinone.
J Clin Microbiol. 2015 Feb;53(2):657-9
Authors: Jones RN, Holliday NM, Rhomberg PR
Tedizolid, a novel oxazolidinone antibacterial with potent activity against a wide range of Gram-positive pathogens, was recently approved by regulatory authorities for the treatment of acute bacterial skin and skin structure infections. A commercial broth microdilution device (Sensititre; Thermo Fisher Scientific) was validated using 285 selected Gram-positive isolates, and the device was documented to have 100.0% essential and categorical agreement with reference MIC results and excellent MIC endpoint reproducibility.
PMID: 25411167 [PubMed - in process]